Potent and selective ALK2 and ALK3 inhibitor (IC50
values are 5 and 30 nM, respectively); inhibits BMP4-mediated Smad1/5/8 activation. Exhibits >200-fold selectivity for BMP signaling over TGF-β
signaling. Also exhibits selectivity over AMPK, PDGFR and MAPK signaling. Promotes neural induction of hPSCs in combination with SB 431542
(Cat.No. 1614). Also induces differentiation of hPSCs into nociceptive sensory neurons in combination with SB 431542
(Cat.No. 1614), SU 5402
(Cat.No.3300), CHIR 99021
(Cat.No. 4423) and DAPT
iPS differentiation with LDN 193189
Image shows IBJ6 human fibroblast induced pluripotent stem cells which have been differentiated into motor neurons. This was performed using a combination of LDN 193189 (100 nM) and SB 431542 (Cat. No. 1614) followed by Retinoic acid (Cat. No. 0695) and Purmorphamine (Cat. No. 4551) culture on Laminin for 18 days. Commitment to the motor neuron fate was accessed using the motor neuron marker anti-Human Islet-1 (red, R&D Systems®, Cat. No. AF1837) and the general neuronal marker, beta III tubulin (green, R&D Systems®, Cat. No. MAB1195). For visualization, the neurons were stained using Northernlights™ 557-conjugated Donkey anti-Goat Secondary Antibody (R&D Systems®, Cat. No. NL001) and Northernlights™ 493-conjugated Donkey anti-Mouse Secondary Antibody (R&D Systems®, Cat. No. NL009).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under exclusive agreement from The Brigham and Women's Hospital Inc. US patents 8,507,501 and 9,045,484
Chemical approaches to stem cell biology and therapeutics.
Li et al.
Cell Stem Cell, 2013;13:270
BMP type I receptor inhibition reduces heterotopic ossification.
Yu et al.
Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors.
Chambers et al.
Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors.
Cuny et al.